Early View

Original article

Characteristics and outcomes of asthmatic patients with COVID-19 pneumonia who require hospitalisation

Antoine Beurnier, Etienne-Marie Jutant, Mitja Jevnikar, Athénaïs Boucly, Jérémie Pichon, Mariana Preda, Marie Frank, Jérémy Laurent, Christian Richard, Xavier Monnet, Jacques Duranteau, Anatole Harrois, Marie-Camille Chaumais, Marie-France Bellin, Nicolas Noël, Sophie Bulifon, Xavier Jaïs, Florence Parent, Andrei Seferian, Laurent Savale, Olivier Sitbon, David Montani, Marc Humbert

Please cite this article as: Beurnier A, Jutant E-M, Jevnikar M, et al. Characteristics and outcomes of asthmatic patients with COVID-19 pneumonia who require hospitalisation. *Eur Respir J* 2020; in press (https://doi.org/10.1183/13993003.01875-2020).

This manuscript has recently been accepted for publication in the *European Respiratory Journal*. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online.

Copyright ©ERS 2020. This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.
Characteristics and outcomes of asthmatic patients with COVID-19 pneumonia who require hospitalization

Antoine Beurnier, MD,1,2,3 Etienne-Marie Jutant, MD,1,2,4 Mitja Jevnikar, MD,1,2,4 Athénaïs Boucly, MD,1,2,4 Jérémy Pichon, MD,1,2,4 Mariana Preda, MD,1,2,4 Marie Frank, MD,5 Jérémy Laurent, MD,5 Christian Richard, MD, PhD,1,6 Xavier Monnet, MD, PhD,1,6 Jacques Duranteau, MD, PhD,1,7 Anatole Harrois, MD, PhD,1,7 Marie-Camille Chaumais, PharmD, PhD,1,2,8 Marie-France Bellin, MD, PhD,1,9 Nicolas Noël MD, PhD,1,10 Sophie Bulifon, MD,1,2,4 Xavier Jaïs, MD,1,2,4, Florence Parent, MD,1,2,4 Andrei Seferian, MD,1,2,4 Laurent Savale, MD, PhD,1,2,4 Olivier Sitbon, MD, PhD,1,2,4 David Montani, MD, PhD,1,2,4, Marc Humbert, MD, PhD,1,2,4*.

1. Université Paris-Saclay, Faculty of Medicine, Le Kremlin-Bicêtre, France
2. INSERM UMR_S 999, Le Kremlin-Bicêtre, France
3. AP-HP, Service de physiologie et d'explorations fonctionnelles respiratoires (CRISALIS / F-CRIN network), Hôpital Bicêtre, Le Kremlin-Bicêtre, France
4. AP-HP, Service de pneumologie et soins intensifs respiratoires, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
5. AP-HP, Département d'information médicale, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
6. AP-HP, Service de médecine intensive-réanimation, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
7. AP-HP, Département d'anesthésie et réanimation, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
8. AP-HP, Service de pharmacie, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
9. AP-HP, Service d'imagerie médicale, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
10. AP-HP, Service de médecine interne, Hôpital Bicêtre, Le Kremlin-Bicêtre, France

*Correspondance:
Pr. Marc Humbert, MD, PhD
Department of Respiratory and Intensive Care Medicine, Le Kremlin-Bicêtre, France
78 rue du général Leclerc, 94270 Le Kremlin Bicêtre, France.
Tél: +33 145 21 79 72
Fax: +33 145 21 79 71
Email: marc.humbert@aphp.fr
ABSTRACT

BACKGROUND: Viral respiratory infections are the main causes of asthma exacerbation. The susceptibility of asthmatics to develop an exacerbation when they present with severe pneumonia due to SARS-CoV-2 infection is unknown. The objective of this study was to investigate the characteristics and outcomes of asthmatic patients with COVID-19 pneumonia who required hospitalization during the spring 2020 outbreak in Paris, France.

METHODS: A prospective cohort follow-up was carried out from March 15 to April 15, 2020 in Bicêtre Hospital, University Paris-Saclay, France. All hospitalized patients with a SARS-CoV-2 infection who reported a history of asthma were included.

RESULTS: Among 768 hospitalized patients, 37 (4.8%) reported a history of asthma, which had been previously confirmed by a pulmonologist in 85% of cases. Patients were mainly female (70%), non-smokers (85%), with a median age of 54 years (interquartile range, IQR 42-67). None of them presented with an asthma exacerbation. Twenty-two (59%) had major comorbidities and 31 (84%) had a body mass index ≥ 25 kg/m². The most common comorbidities were obesity (36%), hypertension (27%) and diabetes (19%). All patients had a confirmed diagnosis of COVID-19 pneumonia on computed tomography of the chest. Eosinopenia was a typical biologic feature with a median count of 0/mm³ (IQR 0-0). Eleven patients (30%) were admitted in intensive care unit with three death (8.1%) occurring in the context of comorbidities.

CONCLUSION: Asthmatics were not overrepresented among patients with severe pneumonia due to SARS-CoV-2 infection who required hospitalization. Worst outcomes were observed mainly in patients with major comorbidities.

Key words: Asthma; COVID-19, SARS-CoV-2
INTRODUCTION

Viral respiratory infections are the main causes of asthma exacerbations in both adults and children. Coronaviruses are commonly isolated in the respiratory tract of these patients [1]. As the world faces the coronavirus disease 2019 (COVID-19) pandemic due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, concerns have arisen about a possible increased risk of asthma exacerbations. Indeed, SARS-CoV-2 is well known for its respiratory tropism that can lead to severe pneumonia and potentially fatal acute respiratory distress syndrome (ARDS) [2]. However, the prevalence of asthma among inpatients with COVID-19 remains debated. In Wuhan, authors pointed out a rate of 0.9% [3], markedly lower than that in the local population; in another study investigating the clinical characteristics and allergy status of 140 patients infected by SARS-CoV-2 in Wuhan, no patient were reported as being asthmatic [3]. Conversely, other authors found that asthmatics accounted for 12.5% of total COVID-19 inpatients in New York [4]. Beside those conflicting statistics, the characteristics and the outcomes of asthmatic patients infected with SARS-CoV-2 have not yet been described in detail.

In France, the Great Paris region (Ile-de-France) has been particularly affected by the epidemic. On March 14, 2020, the Regional Health Agency issued a statement underscoring the rapid spread of SARS-CoV-2 in the region with 376 new daily confirmed cases [5]; the number of regional hospitalizations for COVID-19 eventually reached a peak on April 1st [6]. From March 15, 2020 to April 15, 2020 we carried out a prospective study in Bicêtre Hospital, University Paris-Saclay, France. The objective of this study was to investigate the characteristics and outcomes of asthmatic patients with COVID-19 pneumonia who required hospitalization.
MATERIAL AND METHODS

Patients and study design
A prospective monocentric cohort follow-up was initiated in Bicêtre Hospital, France. All adult patients hospitalized from March 15, 2020 to April 15, 2020 with a diagnosis of SARS-CoV-2 infection and reporting a history of asthma were included. Decision of hospitalization was based on a concerted decision algorithm that has been locally implemented into clinical practice during the French COVID-19 outbreak (supplementary Figure 1). COVID-19 was first suspected on the basis of compatible symptoms: in suspected cases, both SARS-CoV-2 reverse transcription polymerase chain reaction (RT-PCR) on nasopharyngeal swab and computed tomography (CT) of the chest were systematically performed. Diagnosis was confirmed in the presence of positive SARS-CoV-2 RT-PCR and/or typical CT abnormalities (i.e. ground-glass opacities and/or consolidation in the lung periphery) [7]. A random control group of 75 non-asthmatic patients hospitalized for COVID-19 pneumonia in our hospital during the same period has been included and analyzed. Patients received written information about data collection. After inclusion, all data regarding the clinical status, main outcomes, biological and radiological features were recorded in an anonymous database registered to the National Commission on Informatics and Liberty (n° 2217978).

Characteristics at diagnosis and outcomes
The following data were collected after patient-centered interviews: comorbid conditions (obesity, hypertension, diabetes, renal failure, coronary heart disease); current smoking status (“non-smokers” referring to both former and never smokers); history of asthma; asthma controller treatment with classification from step 1 to 5 according to the last 2020 Global Initiative for Asthma (GINA) report [8]; when feasible, we also clarified with the patient or
his family whether asthma diagnosis had been confirmed by a pulmonologist or not. In addition, the following laboratory tests were analyzed at admission: SARS-CoV-2 RT-PCR result, blood count, cardiac biomarkers, liver function, arterial blood gas, C-reactive protein (CRP), fibrinogen, D-dimers, creatine phosphokinase (CPK), lactate dehydrogenase (LDH), ferritin. CT of the chest was analyzed by a radiologist and a pulmonologist and the extent of lesions was classified as mild (< 10%), moderate (10-24%), severe (25-49%), very severe (50-74%), and critical (≥ 75%). The following management strategies were detailed: use of systemic corticosteroids (CS), short-acting beta-agonists (SABA), antibiotics, adjustment of asthma controller, oxygen flow, intensive care unit (ICU) admission, and mechanical ventilation requirement. Finally, the main outcomes (mortality, length of ICU stay and total length of hospital stay) were investigated after a one-month follow-up.

**Statistical methods**

Quantitative data were expressed as median (interquartile range) (IQR, presented as first quartile – third quartile). Qualitative data were expressed as number of occurrence, n (%). In case of missing data, the number of patients with available informations was provided next to each variable. When this number was not specified, data of entire population was available and analyzed. Student's t test or Mann-Whitney U test (if not normally distributed) were used to compare the continuous variables between two groups. Pearson’s chi-square (χ²) test or Fisher’s exact tests if appropriate, were used to compare discrete variables between two groups.
RESULTS

Clinical characteristics of patients hospitalized for COVID-19 pneumonia

Among 768 hospitalized COVID-19 patients, 37 (4.8%) reported a history of asthma. Thirty-one asthmatics had positive SARS-CoV-2 RT-PCR on nasopharyngeal swab (84%). The remaining six were diagnosed on the basis of clinical presentation and radiological patterns [7].

Asthmatic patients were mainly female (70%), non-smokers (85%), with a median age of 54 years (42-67) and a median body mass index (BMI) of 28.3 kg/m² (26.8-31.5). In 85% of cases the diagnosis of asthma had been previously confirmed by a pulmonologist. Eleven patients (30%) were GINA step 5, receiving high doses inhaled CS (ICS) with long-acting-beta agonists (LABA), associated with low dose oral CS in one case, and long-term omalizumab therapy in two (Supplementary Table 1). Thirty-one asthmatics (84%) had a BMI ≥ 25 kg/m². Twenty-two (59%) had at least one major comorbidity. The most common comorbid conditions were obesity (36%), hypertension (27%) and diabetes (19%). Fifteen (41%) had multimorbidities (Table 1).

The median time from onset of symptoms to admission in the emergency room was 6 days (3-8). Fifty percent of patients had an initial peripheral oxygen saturation below 95% while breathing room air and 25% had a respiratory rate above 30/min. None of them presented with an asthma exacerbation. Wheezing, mostly reported as mild, was reported at admission in only 6 cases (16%) (Table 2).

Non-asthmatic controls are presented in Tables 1 and 2. All differences pointed to worst COVID-19 pneumonia in non-asthmatics, as evidenced by older age, higher male/female gender rate, and a trend to more comorbidities.
Biological findings at inclusion

Laboratory values in the emergency room are summarized in Table 3. Among asthmatics, lymphopenia was a frequent finding (median 1,205/mm3, IQR 738-1,476) (Figure 1A). Patients also presented with a marked eosinopenia, 78% having a blood eosinophils count equal to zero (Figure 1B). N-terminal pro-B-type natriuretic peptide (NT-pro BNP) was measured in 21 patients and normal value (< 300 ng/L) was found in 81% of cases. Of 31 available data, 6 patients (19%) had increased high-sensitive cardiac troponin T (≥ 14 ng/L); however, none of these patients demonstrated consistent evidence of serious myocardial injury. Elevation of D-dimers was commonly observed (median 810 µg/L, IQR 483-1,180), as well as increased CRP levels (median CRP 51 mg/L, IQR 27-116). Arterial blood gas while breathing room air was available in 29 patients: hypoxaemia was a common finding (median arterial partial pressure of oxygen (PaO₂) 68 mmHg, IQR 62-83) with hypocapnia (median arterial partial pressure of carbon dioxide (PaCO₂) 34 mmHg, IQR 32-38).

Non-asthmatic controls are presented in Table 3. There was a trend for more pronounced lymphopenia and worst CRP, D-dimers, LDH, liver transaminases levels, with more severe hypoxemia.

Radiological findings

All asthmatics underwent a CT of the chest (Table 4). Peripheral or mixed ground glass opacities were the most frequent CT patterns (95% of cases), expanding over more than 10 percent of lung parenchyma in 76% of cases. Consolidations were observed in 26 patients (70%) and crazy-paving pattern in 13 patients (35%). In 51% of cases, lesions predominated in inferior lobes. Based on clinical judgement or prediction rules [9], four patients had initial CT pulmonary angiography (CTPA), demonstrating two cases of acute pulmonary embolisms
(PE) at admission. Eight additional CTPA were performed during hospital stays for clinical deterioration, leading to another acute PE diagnosis. In this small cohort of patients, higher inhaled corticosteroid exposure was not associated with higher proportion of severe radiological pneumonia; mild pneumonia tended to be more frequent in asthmatics with higher doses of ICS (Supplementary Figure 2).

All non-asthmatic controls had imaging of the chest at admission (66 CT and 9 chest X ray). The results of CT of the chest are presented in Table 4. As compared to asthmatics, there was more severe-to-critical radiological presentation in the non-asthmatics.
Management and outcomes

As shown in Table 5, 30 (81%) asthmatics received oxygen with use of high-concentration masks in 10 patients. When nasal oxygen was used, the median oxygen flow-rate was 2 L/min. In two patients, oxygen had to be maintained after discharge. Thirty-one (84%) received at least one antibiotic. SABA as needed was prescribed using a pressurized metered-dose inhaler (p-MDI) with a spacer chamber and previous inhaled treatments were maintained. Five patients received oral CS before admission, one of them in the context of self-medication. Three additional patients received intravenous CS during hospital stay: refractory ARDS was the main cause of CS prescription in two cases and bronchospasm occurring in the context of mechanical ventilation in one case. Eleven patients were admitted in ICU, six of them requiring invasive mechanical ventilation. There was a trend for more aged and comorbid patients among patients admitted in ICU (Table 6). A flowchart of the main outcomes is presented in Figure 2. As shown in Figure 3, asthmatics without multimorbidities were discharged at home earlier.

Two deaths occurred at one-month follow-up and one additional death was later noted, thus leading to a mortality rate of 8.1% in asthmatics (as compared to 14.6% in non-asthmatics, p=0.381). The first patient was a 68 year-old woman treated for asthma by her pulmonologist with fluticasone/salmeterol 500/50 µg daily (medium doses, GINA step 4). She had several comorbidities including obesity (BMI = 31.2 kg/m²), diabetes, current chemotherapy for ovarian cancer, dyslipidemia and sleep apnea syndrome. At admission, no wheezing was reported, she was eosinopenic (0/mm³), had positive nasal SARS-CoV-2 RT-PCR and presented with mild extent of pulmonary lesions on CT of the chest. Five days after symptoms had started, she was transfered in ICU for acute respiratory failure. No acute PE was detected on CTPA. Due to an extremely poor prognosis, it was decided to restrict advanced life support, including intubation. She died on day 9. The second patient was a 67 year-old
woman with a diagnosis of asthma confirmed by a pulmonologist and treated with inhaled beclometasone/formoterol 200/12 µg daily (low doses, GINA step 3). She also displayed severe obesity (BMI = 43 kg/m²), hypertension, renal failure requiring chronic dialysis and primary biliary cirrhosis. Mild wheezing was noted at admission along with positive nasal SARS-CoV-2 RT-PCR, eosinopenia (0/mm³) and severe extent of pulmonary lesions on CT of the chest. Ten days after symptoms had started, she was intubated in ICU for acute respiratory failure. She died at day 15 from refractory ARDS. The third patient was a 75 year-old hypertensive and overweight woman (BMI=29.4) treated for asthma with budesonide/formoterol 1200/36 µg daily (high doses, GINA step 5). At admission in the emergency room, no wheezing was reported; she was eosinopenic (0/mm³), had positive nasal SARS-CoV-2 RT-PCR and presented with very severe extent of radiological lesions (50-75%). She was intubated 4 days later. Bronchospasm occurred during mechanical ventilation and systemic corticosteroids were administrated at day 12. Withdrawal of mechanical ventilation was not possible: she died at day 45 from respiratory failure.

**Evolution of asthmatics treated with biologics**

Two patients were treated with anti-immunoglobulin E monoclonal antibody (omalizumab) for severe allergic asthma. The first one was a 53 year-old woman treated with budesonide/formoterol 800/12 µg daily, montelukast 10 mg/j and subcutaneous omalizumab at a monthly dose of 300 mg. She had no sign of asthma exacerbation before admission, but took a short course of oral prednisone (40mg/day) during five days as self medication that was stopped at admission. She had positive nasal SARS-CoV-2 RT-PCR, eosinopenia (0/mm³) and a moderate extent of lesions on CT of the chest. She had no evidence of asthma exacerbation nor respiratory failure, allowing discharge at home on day 5.
The second patient was a 78 year-old overweight woman with severe allergic asthma and allergic bronchopulmonary aspergillosis, treated with budesonide/formoterol 800/12 µg daily, oral prednisone 5 mg/j and subcutaneous omalizumab 300 mg twice monthly. She also suffered from hypothyroidism, lumbar spinal stenosis and depression. Initial presentation included crackles and minor wheezing, with positive nasal SARS-CoV-2 RT-PCR, blood eosinophil count of 50/mm³ and severe extent of pneumonia on CT at admission (Figure 4A). Nine days after the beginning of symptoms, she was admitted in ICU for acute respiratory failure. Oro-tracheal intubation was needed and mechanical ventilation was well tolerated with no evidence of bronchospasm. After 8 days of mechanical ventilation, acute bronchospasm appeared for the first time. Aspergillus fumigatus was detected in bronchial secretions. Segmental acute PE was diagnosed 12 days after admission (Figure 4B). Other treatments included anticoagulation, bronchodilator nebulizations, intravenous CS and voriconazole. The next omalizumab injection has been administrated as planned, when she was under mechanical ventilation. No adverse events were observed and successful extubation was possible five days later. She was discharged of ICU after 23 days. At day 75, she was well and alive, still undergoing rehabilitation.
DISCUSSION

This prospective monocentric cohort describes clinical, biological and radiological characteristics and outcomes of asthmatics with COVID-19 pneumonia who require hospitalization. During the spring 2020 outbreak, asthmatics accounted for less than 5% of total hospitalized patients in our institution. The most recent data available in France indicate that 6.4% of individuals have a current diagnosis of asthma [10]. In line with previous reports [11], our results suggest that asthmatics were thus not over-represented among COVID-19 inpatients. In addition, no patient was hospitalized for a COVID-19 related asthma exacerbation during the outbreak and very few developed an asthma attack while hospitalized, which is consistent with data recently reported in Strasbourg, France [12]. This contrasts sharply with viral respiratory infections, including other types of coronavirus, being the main causes of asthma exacerbations [1].

Several mechanisms may explain this apparent paradox. First, a lower expression of SARS-CoV-2 cellular receptor angiotensin-converting enzyme-2 (ACE2) has been described in airways cells of patients with respiratory allergy and/or asthma, and it was also found that ACE2 expression was inversely associated with type 2 biomarkers [13]. Of note, severe eosinopenia was a typical biologic feature in our cohort, 78% of hospitalized asthmatics having no detectable blood eosinophils at admission. This finding is unusual in hospitalized asthmatics receiving neither systemic CS nor anti-interleukin 5 (IL-5) therapy. Similar findings were reported in a mostly non-asthmatic COVID-19 population in Wuhan, China, where eosinopenia was described in 53% of hospitalized subjects [14] and in 81% of fatal cases [15]. As suggested by others [16], eosinopenia in COVID-19 may be a marker of more severe disease. In addition, one may speculate that it reflects a down-regulation of type 2 inflammation that might decrease the risk of asthma exacerbation orchestrated by type 2
responses. Of note, it has been recently showed that severe COVID-19 is driven by inappropriate inflammatory response defined by low levels of type I and III interferons juxtaposed to elevated chemokines and high expression of IL-6, supporting the concept that reduced innate antiviral defenses coupled with exuberant proinflammatory cytokine production are the defining and driving features of COVID-19 [17]. Further studies are needed, describing the cytokine profile of asthmatics in response to SARS-CoV-2 infection. Furthermore, there is in vitro evidence to support a protective effect of ICS on coronaviruses infections [18]. Indeed, sputum analysis showed that ACE2 expression levels are significantly lower in asthma patients taking ICS than in those not taking ICS, especially when high doses are administrated [19]. Randomized control trials are needed to test the effect of ICS on COVID-19 in both asthmatics and non-asthmatics patients.

We observed a female predominance (70%) in our cohort, whereas previous works demonstrated an increased risk of SARS-CoV-2 infection in males [20]. This might be explained by age-related sex ratio differences, asthma being more prevalent in female adults [21][22]. Moreover, obesity, hypertension and diabetes were the most common comorbidities observed in our cohort of hospitalized asthmatics with COVID-19, which is consistent with earlier research in other patient groups [4][23]. Interestingly, obesity has been associated with asthma in women [24] and severe forms of COVID-19 in both genders [25][26].

Asthmatic patients with COVID-19 pneumonia who required hospitalization presented with radiological characteristics similar to those described previously, with a predominance of peripheral ground glass opacities [27]. Interestingly, three patients had a diagnosis of acute PE (8.1 %) on CTPA at admission or during hospitalization. At the start of the COVID-19 outbreak, the first-line imaging tool in our centre relied on non-contrast CT of the chest [7]. However, more concern has been recently raised about thrombosis and pulmonary embolism
in COVID-19 patients [28], underscoring that this complication may be more prevalent in this patient population.

Asthma therapy was unchanged in all patients, including biologics, as recommended by the French Asthma and Allergy Working Group (G2A) [29]. Interestingly, two patients were on omalizumab therapy prior to COVID-19. In one patient, the planned omalizumab injection has been administrated while she was under mechanical ventilation, experiencing severe bronchospasm and ARDS. No adverse events were observed and successful extubation was possible five days later.

Our study included a control group of COVID-19 pneumonia hospitalized in the same hospital during the same period. As compared to controls, asthmatics were younger, more likely to be female and they tended to be less comorbid, which may explain at least in part, the better outcomes in this population. However, it is interesting to note that mild pneumonia tended to be more frequent in asthmatics with higher doses of ICS (supplementary Figure 2). Further studies are needed to investigate the possible positive effect of inhaled corticosteroids on COVID-19 pneumonia as previously showed with dexamethasone in the RECOVERY trial [30]. The ongoing INHASCO trial (NCT04331054) is investigating this research question.

One of the study limitations is the relative small number of asthmatic patients being investigated. However, all patients were identified prospectively by an expert team of asthma specialists in a large University hospital hosting a severe asthma clinic, allowing systematic analysis of relevant information and meticulous follow-up. In a state of emergency, misdiagnoses of both asthma and COVID-19 cannot be excluded. Regarding asthma, it could be underdiagnosed, as diagnosis was based on self-report and pulmonary function tests could not be performed during the outbreak. Asthma might also be overdiagnosed, as previously reported in industrialized countries especially in obese individuals [31]. Nevertheless, asthma
diagnosis had been previously confirmed by a pulmonologist in 85% of cases. A COVID-19 overdiagnosis is also unlikely, with positive SARS-CoV-2 RT-PCR on nasopharyngeal swab in 84% of cases. RT-PCR was negative in only six patients who presented with a high clinical suspicion of COVID-19 and consistent CT of the chest during the outbreak [7].

In conclusion, our data indicate that asthmatics were not over-represented in a large group of hospitalized pneumonia during the spring 2020 COVID-19 outbreak in Paris, France. In addition, COVID-19 pneumonia was not associated with asthma exacerbation at admission and at one-month follow-up in patients who did not modify their asthma treatment including GINA step 5 (high doses ICS with LABA, low dose oral CS, and long-term omalizumab). Large multicenter cohort studies are needed to confirm these data and explore the reasons why SARS-CoV-2 does not seem to trigger as many asthma exacerbations, as previously seen with other respiratory viruses.

**AKNOWLEDGEMENTS**

The authors thank the patients, their families, and all health care professionals and administrative staff from Hospital Bicêtre for their outstanding support. The authors thank the CRISALIS / F-CRIN network (Clinical Research Initiative in Severe Asthma: a Lever for Innovation & Science).
REFERENCES

1. Edwards MR, Bartlett NW, Hussell T, Openshaw P, Johnston SL. The microbiology of asthma. *Nat. Rev. Microbiol.* Nature Publishing Group; 2012; 10: 459–471.

2. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. *JAMA* American Medical Association; 2020; 323: 1061–1069.

3. Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, Shi J, Zhou M, Wu B, Yang Z, Zhang C, Yue J, Zhang Z, Renz H, Liu X, Xie J, Xie M, Zhao J. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. *J. Allergy Clin. Immunol.* 2020; : S0091674920304954.

4. Goyal P, Choi JJ, Pinheiro LC, Schenck EJ, Chen R, Jabri A, Satlin MJ, Campion TR, Nahid M, Ringel JB, Hoffman KL, Alshak MN, Li HA, Wehmeyer GT, Rajan M, Reshetnyak E, Hupert N, Horn EM, Martinez FJ, Gulick RM, Safford MM. Clinical Characteristics of Covid-19 in New York City. *N. Engl. J. Med.* Massachusetts Medical Society; 2020; 0: null.

5. Coronavirus (Covid-19) : points de situation [Internet]. [cited 2020 May 12]. Available from: https://www.iledefrance.ars.sante.fr/coronavirus-covid-19-points-de-situation.

6. SPF. COVID-19 : point épidémiologique du 16 avril 2020 [Internet]. [cited 2020 May 12]. Available from: /maladies-et-traumatismes/maladies-et-infections-respiratoires/infection-a-coronavirus/documents/bulletin-national/covid-19-point-epidemiologique-du-16-avril-2020.

7. Rubin GD, Ryerson CJ, Haramati LB, Sverzellati N, Kanne JP, Raoof S, Schluger NW, Volpi A, Yim J-J, Martin IBK, Anderson DJ, Kong C, Altes T, Bush A, Desai SR, Goldin J, Goo JM, Humbert M, Inoue Y, Kauczor H-U, Luo F, Mazzone PJ, Prokop M, Remy-Jardin M, Richeldi L, Schaefer-Prokop CM, Tomiyama N, Wells AU, Leung AN. The Role of Chest Imaging in Patient Management during the COVID-19 Pandemic: A Multinational Consensus Statement from the Fleischner Society. *Chest* [Internet] 2020 [cited 2020 May 17]; Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7138384/.

8. GINA-2020-full-report_-_final_-_wms.pdf [Internet]. [cited 2020 May 12]. Available from: https://ginasthma.org/wp-content/uploads/2020/04/GINA-2020-full-report_-_final_-_wms.pdf.

9. Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing G-J, Harjola V-P, Huisman MV, Humbert M, Jennings CS, Jiménez D, Kucher N, Lang IM, Lankeit M, Lorusso R, Mazzolai L, Meneveau N, Ni Áinle F, Prandoni P, Pruszczyk P, Righini M, Torbicki A, Van Belle E, Zamorano JL, Galié N, Gibbs JSR, Aboyans V, Ageno W, Agewall S, Almeida AG, Andreotti F, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)The Task Force for the diagnosis and management of acute pulmonary
embolism of the European Society of Cardiology (ESC). Eur. Heart J. 2020; 41: 543–603.

10. Raherison-Semjen C, Izadifar A, Russier M, Rolland C, Aubert J-P, Sellami R, Leynaud D, Fabry-Vendrarc C, Didier A. Prévalence et prise en charge de l’asthme de l’adulte en France en 2018 : enquête ASTHMAPOP. Rev. DÉpidémiologie Santé Publique 2019; 67: S179.

11. Halpin DMG, Faner R, Sibila O, Badia JR, Agusti A. Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection? Lancet Respir. Med. 2020; 8: 436–438.

12. Grandbastien M, Piotin A, Godet J, Abessolo-Amougou I, Ederlé C, Enache I, Fraisse P, Tu Hoang TC, Kassegne L, Labani A, Leyendecker P, Manien L, Marcot C, Pamart G, Renaud-Picard B, Riou M, Doyen V, Kessler R, Fafi-Kremer S, Metz-Favre C, Khayath N, de Blay F. SARS-CoV-2 pneumonia in hospitalized asthmatic patients did not induce severe exacerbation. J. Allergy Clin. Immunol. Pract. [Internet] 2020 [cited 2020 Jul 12]; Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7320869/.

13. Jackson DJ, Busse WW, Bacharier LB, Kattan M, O’Connor GT, Wood RA, Visness CM, Durham SR, Larson D, Enault S, Ober C, Gergen PJ, Becker P, Togias A, Gern JE, Altman MC. Association of Respiratory Allergy, Asthma and Expression of the SARS-CoV-2 Receptor, ACE2. J. Allergy Clin. Immunol. [Internet] 2020 [cited 2020 May 9]; Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7175851/.

14. Zhang J, Dong X, Cao Y, Yuan Y, Yang Y, Yan Y, Akdis CA, Gao Y. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy [Internet] [cited 2020 May 12]; n/aAvailable from: https://onlinelibrary.wiley.com/doi/abs/10.1111/all.14238.

15. Du Y, Tu L, Zhu P, Mu M, Wang R, Yang P, Wang X, Hu C, Ping R, Hu P, Li T, Cao F, Chang C, Hu Q, Jin Y, Xu G. Clinical Features of 85 Fatal Cases of COVID-19 from Wuhan: A Retrospective Observational Study. Am. J. Respir. Crit. Care Med. [Internet] American Thoracic Society - AJRCCM; 2020 [cited 2020 May 16]; Available from: https://www.atsjournals.org/doi/abs/10.1164/rccm.202003-0543OC.

16. Lindsley AW, Schwartz JT, Rothenberg ME. Eosinophil Responses During COVID-19 Infections and Coronavirus Vaccination. J. Allergy Clin. Immunol. 2020; : S0091674920305698.

17. Blanco-Melo D, Nilsson-Payant BE, Liu W-C, Uhl S, Hoagland D, Møller R, Jordan TX, Oishi K, Panis M, Sachs D, Wang TT, Schwartz RE, Lim JK, Albrecht RA, tenOever BR. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. Cell [Internet] 2020 [cited 2020 May 17]; Available from: http://www.sciencedirect.com/science/article/pii/S009286742030489X.

18. Halpin DMG, Singh D, Hadfield RM. Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective. Eur. Respir. J. [Internet] European Respiratory Society; 2020 [cited 2020 May 14]; Available from: https://erj.ersjournals.com/content/early/2020/04/20/13993003.01009-2020.
19. Peters MC, Sajuthi S, Deford P, Christenson S, Rios CL, Montgomery MT, Woodruff PG, Mauger DT, Erzurum SC, Johansson MW, Denlinger LC, Jarjour NN, Castro M, Hastie AT, Moore W, Ortega VE, Bleecker ER, Wenzel SE, Israel E, Levy BD, Seibold MA, Fahy JV. COVID-19 Related Genes in Sputum Cells in Asthma: Relationship to Demographic Features and Corticosteroids. *Am. J. Respir. Crit. Care Med.* [Internet] American Thoracic Society - AJRCCM; 2020 [cited 2020 May 14]; Available from: https://www.atsjournals.org/doi/abs/10.1164/rccm.202003-0821OC.

20. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *The Lancet* Elsevier; 2020; 395: 507–513.

21. Schatz M, Camargo CA. The relationship of sex to asthma prevalence, health care utilization, and medications in a large managed care organization. *Ann. Allergy. Asthma. Immunol.* Elsevier; 2003; 91: 553–558.

22. Zein JG, Denson JL, Wechsler ME. Asthma over the Adult Life Course: Gender and Hormonal Influences. *Clin. Chest Med.* 2019; 40: 149–161.

23. Guan W, Liang W, Zhao Y, Liang H, Chen Z, Li Y, Liu X, Chen R, Tang C, Wang T, Ou C, Li L, Chen P, Sang L, Wang W, Li J, Li C, Ou L, Cheng B, Xiong S, Ni Z, Xiang J, Hu Y, Liu L, Shan H, Lei C, Peng Y, Wei L, Liu Y, Hu Y, et al. Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis. *Eur. Respir. J.* [Internet] 2020 [cited 2020 May 14]; Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7098485/.

24. Chen Y, Dales R, Tang M, Krewski D. Obesity May Increase the Incidence of Asthma in Women but Not in Men: Longitudinal Observations from the Canadian National Population Health Surveys. *Am. J. Epidemiol.* Oxford Academic; 2002; 155: 191–197.

25. Simonnet A, Chetboun M, Poissy J, Raverdy V, Nourlette J, Duhamel A, Labreuche J, Mathieu D, Pattou F, Jourdain M. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. *Obesity* [Internet] [cited 2020 May 13]; n/aAvailable from: https://onlinelibrary.wiley.com/doi/abs/10.1002/oby.22831.

26. Sattar Naveed, McInnes Iain B., McMurray John J. V. Obesity a Risk Factor for Severe COVID-19 Infection: Multiple Potential Mechanisms. *Circulation* [Internet] American Heart Association; [cited 2020 May 13]; 0Available from: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.120.047659.

27. Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, Fan Y, Zheng C. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. *Lancet Infect. Dis.* 2020; 20: 425–434.

28. Bompard F, Monnier H, Saab I, Tordjman M, Abdoul H, Fournier L, Sanchez O, Lorut C, Chassagnon G, Revel M. Pulmonary embolism in patients with Covid-19 pneumonia. *Eur. Respir. J.* [Internet] European Respiratory Society; 2020 [cited 2020 May 16]; Available from: https://erj.ersjournals.com/content/early/2020/05/07/13993003.01365-2020.
29. COVID-asthma_CRISALIS-EN.pdf [Internet], [cited 2020 May 16]. Available from: http://splf.fr/wp-content/uploads/2020/04/COVID-asthma_CRISALIS-EN.pdf.

30. Horby P, Lim WS, Emberson J, Mafham M, Bell J, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, Prudon B, Green C, Felton T, Chadwick D, Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, Jefferies K, Montgomery A, Rowan K, Juszczak E, Baillie JK, Haynes R, Landray MJ, Group RC. Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report. medRxiv Cold Spring Harbor Laboratory Press; 2020; : 2020.06.22.20137273.

31. Aaron SD, Vandemheen KL, Boulet L-P, McIvor RA, FitzGerald JM, Hernandez P, Lemiere C, Sharma S, Field SK, Alvarez GG, Dales RE, Doucette S, Fergusson D. Overdiagnosis of asthma in obese and nonobese adults. CMAJ Can. Med. Assoc. J. 2008; 179: 1121–1131.
**Table 1. Patients characteristics and medical history at inclusion**

| Patients characteristics | Asthmatics (n = 37) | Controls (n = 75) | p-value |
|--------------------------|---------------------|------------------|---------|
| Age (years)              | 54 (42-67)          | 60 (52-70)       | 0.019   |
| Gender, male/female      | 11 (30) / 26 (70)   | 49 (65) / 26 (35)| < 0.001|
| BMI (kg/m²)              | 28.3 (26.8-31.5)    | 28.7 (26.8-31.2) | 0.856   |
| Tobacco exposure          |                     |                  |         |
| Current/former smokers   | 12 (32)             | 18 (24)          | 0.343   |
| Never smokers            | 25 (68)             | 57 (76)          | 0.343   |
| Comorbid conditions      |                     |                  |         |
| 1. Obesity               | 13 (36)             | 24/65 (37)       | 0.901   |
| Class I (30 ≤ BMI < 35)  | 5                   | 17               |         |
| Class II (35 ≤ BMI < 40) | 6                   | 4                |         |
| Class III (BMI ≥ 40)     | 2                   | 3                |         |
| 2. Overweight (25 ≤ BMI < 30) | 18 (49)           | 35/65 (54)      | 0.613   |
| 3. Hypertension          | 10 (27)             | 32 (43)         | 0.161   |
| 4. Diabetes              | 7 (19)              | 17 (23)         | 0.834   |
| 5. Renal failure         | 3 (8)               | 6 (8)          | 1.000   |
| Dialysis                 | 2                   | 3                |         |
| Nephrectomy              | 1                   | 0                |         |
| 6. Coronary heart disease| 2 (5)               | 6 (8)          | 1.000   |
| At least two of the six  | 15 (41)             | 35/67 (52)      | 0.253   |

Quantitative data are expressed as median (IQR). IQR is presented as first quartile (Q1) – third quartile (Q3). Qualitative data are expressed as number of occurrence, n (% of total). In case of variable with missing data, the number of patients with available information is specified. BMI: body mass index; GINA step refers to the treatment strategy proposed in the 2020 Global Initiative for Asthma report [8]; IQR: interquartile range. # 65 available data.
| Variable                          | Asthmatics (n = 37) | Controls (n = 75) | p-value | Available data, n (asthmatics, controls) |
|----------------------------------|---------------------|------------------|---------|----------------------------------------|
| Time since onset of symptoms, days | 6 (3-8)             | 7 (3-10)         | 0.239   | 37, 75                                 |
| Systolic blood pressure, mmHg    | 132 (123-145)       | 138 (122-151)    | 0.457   | 36, 73                                 |
| Diastolic blood pressure, mmHg   | 81 (71-89)          | 79 (69-88)       | 0.993   | 36, 73                                 |
| Heart rate, min⁻¹                | 99 (88-111)         | 100 (89-109)     | 0.714   | 36, 73                                 |
| Temperature, °C                  | 38.1 (37.3-38.7)    | 38.2 (37.4-38.7) | 0.899   | 36, 74                                 |
| Respiratory rate, min⁻¹          | 26 (20-30)          | 28 (20-32)       | 0.361   | 31, 62                                 |
| SpO₂ while breathing room air, % | 95 (92-97)          | 93 (89-95)       | 0.008   | 35, 71                                 |
| Wheezing                         | 6 (16)              | 2 (3)            | 0.015   | 37, 75                                 |
|  Mild wheezing                   | 5                   | 0                |         | 37, 75                                 |
|  Severe wheezing                 | 1                   | 2                |         | 37, 75                                 |
Quantitative data are expressed as median (IQR). IQR is presented as first quartile (Q1) – third quartile (Q3). Qualitative data are expressed as number of occurrence, n (% of total).

IQR: interquartile range; SpO₂: oxygen peripheral saturation.
| Variable                  | Asthmatics (n = 37)          | Controls (n = 75)          | p-value | Available data, n (asthmatics, controls) |
|---------------------------|------------------------------|----------------------------|---------|------------------------------------------|
| Leucocytes, mm$^{-3}$     | 6,990 (5,710-9,020)          | 6,690 (5,330-9,483)       | 0.719   | 37, 74                                   |
| Haemoglobin, g/dL         | 13.0 (12.3-14.7)             | 13.5 (12.6-14.6)          | 0.819   | 37, 74                                   |
| Platelets, mm$^{-3}$      | 213,000 (159,000-239,000)    | 206,000 (165,000-254,000) | 0.699   | 37, 74                                   |
| Neutrophils, mm$^{-3}$    | 5,225 (3,835-6,910)          | 5,160 (3,815-7,698)       | 0.883   | 36, 74                                   |
| Eosinophils, mm$^{-3}$    | 0 (0-0)                      | 0 (0-0)                   | 0.254   | 36, 74                                   |
| Lymphocytes, mm$^{-3}$    | 1,205 (738-1,475)            | 890 (623-1,308)           | 0.151   | 36, 74                                   |
| Fibrinogen, g/L           | 5.2 (4.2-6.2)                | 6.1 (5.1-7.2)             | **0.002** | 35, 73                        |
| D-dimers, µg/L            | 810 (483-1,180)              | 1080 (680-1,508)          | 0.329   | 34, 64                                   |
| CRP, mg/L                 | 51 (27-116)                  | 86 (51-174)               | **0.040** | 37, 75                        |
| LDH, UI/L                 | 283 (235-359)                | 392 (311-512)             | **0.005** | 31, 66                        |
| CPK, UI/L                 | 100 (62-160)                 | 189 (84-390)              | 0.245   | 33, 71                                   |
| ASAT, UI/L                | 38 (25-62)                   | 51 (39-73)                | **0.022** | 33, 69                        |
| ALAT, UI/L                | 30 (23-47)                   | 37 (27-64)                | 0.058   | 34, 71                                   |
| Bilirubin, mg/L           | 6 (4-8)                      | 9 (6-13)                  | 0.157   | 34, 71                                   |
| Troponin T HS, ng/L       | 6 (4-13)                     | 12 (8-21)                 | 0.119   | 31, 64                                   |
| Nt-pro BNP, ng/L          | 131 (52-214)                 | 230 (54-1,713)            | 0.745   | 21, 44                                   |
| Ferritin, ng/mL           | 632 (460-985)                | 1,626 (903-3,031)         | **0.034** | 8, 15                                    |
| PaO$$_2$$ in room air, mmHg | 68 (62-83)               | 63 (52-74)                | **0.010** | 29, 61                                    |
| PaCO$$_2$$ in room air, mmHg | 34 (32-38)                | 35 (32-38)                | 0.762   | 29, 61                                   |
Data are expressed as median (IQR). IQR is presented as first quartile (Q1) – third quartile (Q3). ALAT: alanine aminotransferase; ASAT: aspartate transaminase; CPK: creatine phosphokinase; CRP: C-Reactive Protein; IQR: interquartile range; LDH: lactate dehydrogenase; Nt-pro BNP: N-terminal pro-B-type natriuretic peptide; PaCO2: arterial partial pressure of carbon dioxide; PaO2: arterial partial pressure of oxygen; Troponin T HS: high-sensitive cardiac troponin T.
Table 4. Computed of the chest features of COVID-19 pneumonia

| Variable                        | Asthmatics (n = 37) | Controls (n = 75)* | p-value |
|---------------------------------|---------------------|--------------------|---------|
| Ground glass opacities         | 36 (97)             | 64 (97)            | 1.000   |
| Consolidations                  | 26 (70)             | 56 (85)            | 0.132   |
| Lower lobes predominance       | 19 (51)             | 44 (67)            | 0.187   |
| Crazy paving                    | 13 (38)             | 30 (45)            | 0.453   |
| Topography                      |                     |                    |         |
| Peripheral                      | 22 (59)             | 39 (59)            | 0.971   |
| Central                         | 1 (3)               | 1 (2)              | 1.000   |
| Mixed                           | 14 (38)             | 26 (39)            | 0.876   |
| Lesion extent                   |                     |                    |         |
| Mild (< 10 %)                   | 9 (24)              | 6 (9)              | 0.035   |
| Moderate (10-25 %)              | 15 (41)             | 18 (27)            | 0.166   |
| Severe (25-50 %)                | 11 (30)             | 31 (47)            | 0.088   |
| Very severe (50-75 %)           | 1 (3)               | 10 (16)            | 0.050   |
| Critical (> 75 %)               | 1 (3)               | 1 (1)              | 1.000   |
| Mild-to-moderate                | 24 (65)             | 24 (36)            | 0.005   |
| Severe-to-critical              | 13 (35)             | 42 (64)            | 0.005   |

*Data are expressed as number of occurrence, n (% of total). *66 available data
Table 5. Management of asthmatic patients with COVID-19

| Management                                                                 |        |
|---------------------------------------------------------------------------|--------|
| Oxygen                                                                    | 30 (81)|
| Antibiotic(s)                                                             | 31 (84)|
| Azithromycin                                                              | 16 (52)|
| IV or oral CS for asthma exacerbation during hospitalization              | 1 (3)  |
| SABA prescription                                                         | 31/36 (86)|
| pMDI + spacer chamber                                                     | 29/31 (94)|
| DPI                                                                       | 2/31 (6) |
| Nebulized                                                                 | 4/31 (13)|
| Asthma controller treatment adjustment                                    |        |
| Maintenance                                                               | 33/35 (94)|
| Stepped-up                                                                | 1/35 (3) |

Quantitative data are expressed as median (IQR). IQR is presented as first quartile (Q1) – third quartile (Q3). Qualitative data are expressed as number of occurrences, n (% of total). In case of variable with missing data, the number of patients with available information is specified. CS: corticosteroids; DPI: dry powder inhaler; IQR: interquartile range; IV: intravenous; pMDI: pressurized metered-dose inhaler; SABA: short-acting bronchodilators.
Table 6. Description of asthmatics admitted or not in ICU

| Patients characteristics | ICU (n = 11) | No ICU (n = 26) | p value |
|--------------------------|-------------|----------------|---------|
| Age (years)              | 61 (50-68)  | 50 (41-61)     | 0.162   |
| Gender, male/female      | 4 (26) / 7 (64) | 7 (17) / 19 (73) | 0.699   |
| BMI (kg/m²)              | 29 (28-32)  | 28 (25-31)     | 0.144   |
| Tobacco exposure :       |             |                |         |
| Current/former smokers   | 3 (27)      | 9 (35)         | 1.000   |
| Never smokers            | 8 (73)      | 17 (65)        | 1.000   |
| Asthma management        |             |                |         |
| No ICS                   | 2 (18)      | 10 (38)        | 0.279   |
| Low/medium dose ICS      | 4 (36)      | 10 (38)        | 1.000   |
| High dose ICS            | 5 (45)      | 6 (24)         | 0.244   |
| Biologic therapy (omalizumab) | 1 (9)      | 1 (4)         |         |
| Oral corticosteroids     | 1 (9)       | 0 (0)          |         |
| Comorbid conditions      |             |                |         |
| 1. Obesity (BMI ≥ 30)    | 5 (45)      | 8 (31)         | 0.465   |
| 2. Overweight (25 ≤ BMI < 30) | 6 (55)   | 12 (46)       | 0.728   |
| 3. Hypertension          | 6 (55)      | 5 (19)         | 0.051   |
| 4. Diabetes              | 1 (9)       | 6 (32)         | 0.649   |
| 5. Renal failure         | 1 (9)       | 2 (8)          | 1.000   |
| 6. Coronary heart disease| 0 (0)       | 2 (8)          | 1.000   |
| At least two of the six  | 7 (64)      | 8 (31)         | 0.080   |

Quantitative data are expressed as median (IQR). IQR is presented as first quartile (Q1) – third quartile (Q3). Qualitative data are expressed as number of occurrences, n (% of total). BMI: body mass index; ICS: inhaled corticosteroids; ICU: intensive care unit.
Figure 1. Blood lymphocyte (A) and eosinophil (B) count at admission
Figure 2. Outcomes of patients with COVID-19 pneumonia

A. Asthmatics, n = 37
   
   26 discharged at home (70%)
   Median days of hospitalisation = 6.0 (3.3-9.0)

   ICU admission, n = 11 (30%)
   
   1 death (D9)
   4 discharged at home (D13, D15, D23, D23)

   Orotracheal intubation, n = 6 (16%)
   
   2 deaths (D15, D45)
   3 discharged at home (D45, D63 and D71)

   1 patient was still in rehabilitation care at D75
B.

Controls, n = 75

4 deaths (D4, D6, D13, D16)  \rightarrow  38 discharged at home (51%)
Median days of hospitalisation = 8.0 (6.0-10.5)

ICU admission, n = 33 (44%)

2 deaths (both at D4)  \rightarrow  16 discharged at home
Median days of ICU = 3.5 (2-6)

Orotracheal intubation, n = 15 (20%)

5 deaths (D7, D8, D13, D18, D25)  \rightarrow  7 discharged at home (D12, D15, D16, D19, D20, D21, D28)
Figure 3. Proportion of asthmatics discharged at home at 30 days according to the number of their comorbidities

Discharged at home at 30 days

Days of hospitalization

0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%

0 5 10 15 20 25 30

p = 0.01

< 2 comorbidities  ≥ 2 comorbidities
Figure 4. Computed tomography of the chest of the same patient with severe allergic asthma at day 1 (A) and day 12 (B) of hospitalization.

A. Typical extended ground glass opacities with crazy-paving pattern (solid arrow) and nodular consolidations (dashed arrow).

B. Computed tomography with pulmonary angiography revealing acute pulmonary embolism in the right lower lobe pulmonary artery (white arrow).
SUPPLEMENTARY DATA

Figure S1. Decision algorithm in Bicêtre Hospital, during the spring 2020 COVID-19 outbreak

Suspected or confirmed COVID-19*

- Patient without symptoms of respiratory failure (SpO2 ≥ 96%, RR < 20/min) and without dyspnea and without risk factor
  - Discharge with COVIDOM ambulatory follow-up

- Patient with signs of respiratory failure (RR > 30/min and/or need for at least 6 L/min of oxygen in order to obtain SpO2 ≥ 96%)
  - CT of the chest if patient can be stabilized; consider admission in ICU

- Patient with dyspnea and/or RR > 20/min and/or need for oxygen in order to obtain SpO2 ≥ 96% and/or at least one risk factor
  - CT of the chest at the emergency department; hospitalization

COVIDOM is the French ambulatory follow-up health care program for patients with COVID-19; ICU: intensive care unit; SpO2: oxygen peripheral saturation while breathing room air; RR: respiratory rate; *COVID-19 was highly suspected if symptoms and/or CT-scan were typical; diagnosis was confirmed by positive RT-PCR. #List of risk factors: age > 65 years; obesity; chronic respiratory failure; heart failure; renal failure; cirrhosis; diabetes; immunosuppression/cancer; pregnancy.
Figure S2. Pneumonia severity according to ICS doses

ICS: inhaled corticosteroids
### Table S1. Daily doses of asthma controller at admission

|                              |      |
|------------------------------|------|
| **SABA alone**               | 11 (30) |
| Salbutamol 100 µg p.r.n      | 9    |
| Terbutaline 500 mg p.r.n     | 2    |
| **LTRA (GINA 2)**            | 1 (2) |
| Montelukast, 10 mg           | 1    |
| **Medium dose ICS (GINA 2)** | 1 (2) |
| Non-extrafine particle beclometasone pMDI, 1000µg | 1 |
| **Low-dose ICS/LABA (GINA 3)** | 5 (14) |
| Fluticasone furoate/vilanterol DPI, 92/22 µg | 1 |
| Budesonide/formoterol DPI, 400/12 µg | 4 |
| **Medium-dose ICS/LABA (GINA 4)** | 8 (22) |
| Fluticasone propionate/salmeterol pMDI, 500/50 µg | 1 |
| DPI, 500/100 µg              | 2    |
| Extrafine particle beclometasone/formoterol pMDI, 400/24 µg | 4 |
| Add-on montelukast, 10 mg    | 1    |
| DPI, 400/12 µg               | 1    |
| **High-dose ICS/LABA (GINA 5)** | 11 (30) |
| Fluticasone propionate/salmeterol DPI, 1000/100 µg | 5 |
| Add-on tiotropium SMI, 5µg  | 1    |
| DPI, 2000/200 µg             | 1    |
| pMDI, 1000/100 µg            | 1    |
| Extrafine particle beclometasone/formoterol DPI, 800/24 µg | 1 |
| Budesonide/formoterol DPI, 1600/48 µg | 3 |
| Add-on omalizumab, 300 mg twice monthly | 2 |
| Add-on oral CS, 5 mg daily   | 1    |

CS: corticosteroids; DPI: dry powder inhaler; LTRA: leukotriene receptor antagonist; pMDI: pressurized metered-dose inhaler; SABA: short-acting bronchodilators.